Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. For Prescriptions It’s Home Sweet Home for Patients…
A wide array of voices from across the country are calling on lawmakers to oppose recently reintroduced legislation, the Pharmacy Benefit Manager Transparency Act (S.127), which fundamentally misconstrues the role of pharmacy benefit companies, unfairly proposes to take away employers’
Ike Brannon, former senior economist for the United States Treasury and U.S. Congress, and Anthony Lo Sasso, professor of economics at DePaul University, explain the role of pharmacy benefit companies in the prescription drug supply chain in a new Forbes
Over the last five years, the marketplace for independent pharmacies has experienced small fluctuations from year-to-year sometimes gaining stores, sometimes losing stores. These recent fluctuations in the overall number of stores have not dramatically shifted the independent pharmacy market.
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. P&T COMMITTEES FOLLOW THE SCIENCE… Covering effective drugs for the broad
Approximately 9 in 10 Employers Find Pharmacy Benefit Companies Valuable When Designing their Pharmacy Benefits and Say Flexibility and Choice are Essential In case you missed it, the Coalition for Affordable Prescription Drugs (CAPD), an organization that represents a diverse
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed are generics or biosimilars. During last week’s hearing in the House Oversight Committee, Dr. Rena
As Congress reviews legislation targeting Americans’ pharmacy benefits, Members of Congress are raising concerns about the unintended risks of significantly increasing drug costs. In case you missed it, Senator Rand Paul (R-KY) discusses recent legislation advanced by the Senate’s HELP
©2024 PCMA. All Rights Reserved.
